Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy.

Manon Bosseler, Vanessa Marani, Angelina Broukou, Amandine Lequeux,Tony Kaoma, Vincent Schlesser, Jean-Hugues François,Valérie Palissot,Guy J Berchem,Nasséra Aouali,Bassam Janji

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES(2018)

引用 9|浏览8
暂无评分
摘要
The introduction of novel frontline agents in multiple myeloma (MM), like immunomodulatory drugs and proteasome inhibitors, has improved the overall survival of patients. Yet, MM is still not curable, and drug resistance (DR) remains the main challenge. To improve the understanding of DR in MM, we established a resistant cell line (MOLP8/R). The exploration of DR mechanisms yielded an overexpression of HIF1, due to impaired proteasome activity of MOLP8/R. We show that MOLP8/R, like other tumor cells, overexpressing HIF1, have an increased resistance to the immune system. By exploring the main target genes regulated by HIF1, we could not show an overexpression of these targets in MOLP8/R. We, however, show that MOLP8/R cells display a very high overexpression of LCP1 gene (l-Plastin) controlled by HIF1, and that this overexpression also exists in MM patient samples. The l-Plastin activity is controlled by its phosphorylation in Ser5. We further show that the inhibition of l-Plastin phosphorylation restores the sensitivity of MOLP8/R to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). Our results reveal a new target gene of DR, controlled by HIF1.
更多
查看译文
关键词
drug resistance,MM,IMiDs,PIs,HIF1,l-Plastin
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要